CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

bi 754091

mAbexperimental

Clinical trial activity

27 trials · 13 clinical orgs · 0 marketing orgs

Phase 1
22
Phase 2
7
Phase 3
1
Phase 4
0

Earliest trial started Nov 21, 2016 (NCT02952248)

Timeline

2010s

  1. Jan 1, 2016

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2019

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2024

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • bi 754091

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06370871Phase 3Jun 27, 2024Boehringer Ingelheim
NCT06091930Phase 1Jan 15, 2024Boehringer Ingelheim
NCT06084689Phase 2Jan 1, 2024Boehringer Ingelheim, Institut Bergonié
NCT05879978Phase 1/Phase 2 (Phase 2)May 31, 2023Boehringer Ingelheim
NCT05846516Phase 1Mar 13, 2023Amal Therapeutics, Boehringer Ingelheim, New York University, University of Texas at Houston
NCT05471856Phase 1Jan 9, 2023Boehringer Ingelheim
NCT05446129Phase 1Sep 27, 2022Boehringer Ingelheim
NCT05327946Phase 1May 9, 2022Boehringer Ingelheim
NCT05249426Phase 1Feb 25, 2022Boehringer Ingelheim
NCT05155332Phase 1Jan 5, 2022Boehringer Ingelheim
NCT05068102Phase 1Nov 16, 2021Boehringer Ingelheim
NCT04958239Phase 1Sep 24, 2021Boehringer Ingelheim
NCT04839471Phase 2Aug 6, 2021Chang Gung University, China Medical University, Government of Taiwan, Kaohsiung Medical University, National Cheng Kung University, Taipei Veteran General hospital, Taiwan Cooperative Oncology Group
NCT04752215Phase 1May 12, 2021Boehringer Ingelheim
NCT04653142Phase 1Dec 14, 2020Boehringer Ingelheim
NCT04499352Phase 2Sep 14, 2020Boehringer Ingelheim
NCT04147234Phase 1Dec 9, 2019Boehringer Ingelheim
NCT04138823Phase 1Nov 11, 2019Boehringer Ingelheim
NCT04046445Phase 1/Phase 2 (Phase 2)Jul 22, 2019Amal Therapeutics, Boehringer Ingelheim, University of Texas at Houston
NCT03972150Phase 1Jun 12, 2019Boehringer Ingelheim
Showing 20 of 27 trials
Page 1 / 2

Organizations

Research & Development (13)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Boehringer IngelheimFor profit262232016
Amal TherapeuticsFor profit2222019
University of Texas at HoustonAcademic/Hospital2022019
Chang Gung UniversityAcademic/Hospital1012021
China Medical UniversityAcademic/Hospital1012021
Government of TaiwanGovernment1112021
Institut BergoniéAcademic/Hospital1112024
Kaohsiung Medical UniversityAcademic/Hospital1012021
National Cheng Kung UniversityAcademic/Hospital1012021
New York UniversityAcademic/Hospital1012023
OSE ImmunotherapeuticsFor profit1112019
Taipei Veteran General hospitalGovernment1012021
Taiwan Cooperative Oncology GroupAcademic/Hospital1012021
13 organizations
Page 1 / 1